Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared on LinkedIn:
“The therapeutic landscape of early-stage NSCLC is evolving fast with the integration of novel biomarkers and the expansion of perioperative strategies to oncogene-addicted tumors.
In this comprehensive Review just out in The Lancet Respiratory Medicine led and co-ordinated by amazing Jordi Remon we elaborate on the current landscape and discuss ongoing challenges for the implementation of novel strategies in clinical practice.
Main points:
- While neoadjuvant and perioperative immune strategies and adjuvant targeted therapies are rapidly reshaping the management of resectable early-stage non-small-cell lung cancer, their role in borderline resectable tumours remains hypothesis generating.
- The debate between neoadjuvant and perioperative immune strategies remain open. Until prospective data become available, treatment decisions should ideally be individualised and should consider pathological response, clinical risk factors, toxic effects, and patient preferences.
- Immune microenvironment heterogeneity influences response to perioperative immunotherapy, highlighting the need for better biomarker-driven stratification.
- Emerging data suggest the clinically meaningful benefits of EGFR-directed and ALK-directed strategies, but optimal patient selection and treatment sequencing remain uncertain.
- Key clinical questions remain unresolved, including the role of combination versus monotherapy approaches and the generalisability of perioperative strategies across disease stages.”
Title: Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges
Authors: Jordi Remon, Tina Cascone, Stephanie P L Saw, Nikolaj Frost, Molly S C Li, Lizza E L Hendriks, Antonin Levy, Alessandro Di Federico, Jamie E Chaft, Karim Abdelhamid, Mark Awad, Giannis Mountzios, Solange Peters
Limited-time access to full manuscript.
_____
Giannis Mountzios was recognized among OncoDaily’s The 100 Most Influential People in Oncology in 2025, highlighting his contributions to the field of oncology.
Nominations for 100 Influential People in Oncology 2026 are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15: 100 Influential People in Oncology 2026 – Nominations are Open!
You may also find this interesting:
